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OBJECTIVES We sought to assess the role of insulin-like growth factor-I (IGF-I) in muscle wasting in
chronic heart failure (CHF), serum concentrations and local muscular IGF-I expression were
determined in patients with severe CHF.
BACKGROUND Chronic heart failure is associated with progressive muscle atrophy, leading to cardiac
cachexia. Skeletal muscle disuse and inflammatory activation with elevated cytokine levels
have been implicated; however, the pathomechanism involved remains largely unknown.
METHODS Serum levels of IGF-I were measured by competitive solid phase immunoassay in 47 patients
with severe CHF (left ventricular ejection fraction 30%) and 15 age-matched healthy
subjects (HS). Insulin-like growth factor-I and IGF-I receptor expression were assessed in
vastus lateralis biopsies by real-time PCR and Western blot analysis.
RESULTS Although serum IGF-I was not significantly different (175  10 ng/ml in CHF vs. 170 
12 ng/ml in HS, p  NS), local muscle IGF-I mRNA expression was reduced by 52% in
CHF (6.7  0.4 vs. 14.0  0.9 arbitrary units in HS, p  0.001). This was accompanied by
an increase in IGF-I receptor mRNA expression (86.8 5.4 in CHF vs. 23.1 1.8 arbitrary
units in HS, p  0.001). Local IGF-I expression was significantly correlated with muscle
cross-sectional area (R  0.75, p  0.01). Chronic heart failure patients with a body mass
index of 25 kg/m2 showed signs of peripheral growth hormone (GH) resistance, as
indicated by elevated serum GH, and reduced IGF-I levels.
CONCLUSIONS In CHF patients, muscle IGF-I expression is considerably reduced in the presence of normal
serum IGF-I levels, possibly contributing to early loss of muscle mass. These findings are
consistent with a potential role of IGF-I for skeletal muscle atrophy in CHF. (J Am Coll
Cardiol 2002;39:1175–81) © 2002 by the American College of Cardiology Foundation
In recent years it has become widely accepted that the
catabolic syndrome associated with advanced stages of
chronic heart failure (CHF) is more than a symptom of
disease progression; cardiac cachexia has been shown to be
correlated with lower exercise tolerance and reduced survival
(1). However, the process leading to progressive loss of
muscle mass and exercise capacity, finally resulting in
cardiac cachexia, is still not completely understood.
Muscle wasting starts long before the clinical signs of
overt cachexia become apparent. It has already been docu-
mented that noncachectic patients with CHF show reduced
leg lean tissue compared with healthy subjects (HS) (2),
suggesting that the factors responsible for the initiation of
the catabolic process may be present at early stages of the
heart failure syndrome.
Until now a number of different humoral factors have
been accused of being responsible for the catabolic process
in CHF, among them elevated serum cytokines (3) and
catecholamines (4), cortisol/dihydroepiandrosterone imbal-
ance (5) and growth hormone (GH) resistance (5). A
possible causal relationship between these factors and the
catabolic syndrome was inferred based on the presumption
that serum hormone levels are representative of local con-
centrations in target organs—most notably the skeletal
muscle. However, this presumption has not been validated.
In the context of the present study we focused on the
GH/IGF-I axis (GH/IGF-I)—a key system involved in
regulation of normal cell growth, hypertrophy and atrophy.
It has been shown that, in patients with CHF, low levels of
systemic IGF-I are associated with a decreased leg muscle
cross-sectional area and strength (6). We therefore hypoth-
esized that the GH/IGF-I axis may be involved in the
pathogenesis of skeletal muscle catabolism and dysfunction
in CHF. Insulin-like growth factor-I exerts its functions via
both autocrine and paracrine pathways. In order to assess
the relation between local and systemic concentrations of
IGF-I and GH the serum IGF-I and GH levels were
measured and compared to the local expression of IGF-I
and IGF-I receptor in the quadriceps muscle and nonca-
chectic patients with CHF and of HS.
METHODS
Patient selection and study protocol. Forty-seven male
patients 70 years old with CHF (NYHA functional class
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II to IV) as a result of dilated cardiomyopathy (DCM) or
ischemic heart disease (IHD) were included in this study.
All 47 patients had clinical, radiological and echocardio-
graphic signs of CHF and a severely reduced left ventricular
ejection fraction (LVEF) 30% as assessed by left ventricu-
lography.
A total of 15 age-matched male patients (age 58.3 
3.2 years), who were admitted for nonspecific chest pain to
rule out coronary artery disease, served as HS. They were
normal by physical examination, ECG, chest X-ray, two-
dimensional echocardiography, coronary angiography and
left ventriculogram (LVEF 70  2%). Healthy subjects had
no evidence of hypertension or diabetes mellitus and had
normal findings on routine hematologic and biochemical
blood analyses. They were on no medication before or
during the study period.
The protocol of this study was approved by the Ethics
Committee of the University of Leipzig, and written in-
formed consent was obtained from all patients and HS
before enrollment.
Exercise testing and respiratory variables. Exercise test-
ing was performed on a calibrated, electronically braked
bicycle in an upright position, with work load increasing
progressively every 3 min in steps of 25 W, beginning at
25 W. Respiratory gas exchange data were determined
continuously throughout the exercise test, as previously
described (7).
Measurement of parameters of the GH/IGF-I axis and
tumor necrosis factor-. Blood samples were collected
from both study groups in the morning, after a fasting
period of 12 h. Growth hormone was measured by
immunofluorometric assay using the AutoDELFIA System
(Wallac, Turku, Finland) with a sensitivity of 15 pg/ml
for GH. Intraassay and interassay coefficients of variation
for GH were determined to be below 4.1%, in the range of
2.5 to 15 ng/ml. Serum levels of IGF-I were measured after
acid ethanol extraction by a competitive solid phase immu-
noassay, according to the method of Kratzsch et al. (8). This
assay was modified by the use of biotin for labeling of IGF-I
and streptavidin-europium (Wallac, Turku, Finland) for the
detection of labeled molecules by time-resolved fluores-
cence. The sensitivity of the assay was below 0.9 ng/ml.
Intraassay and interassay coefficients of variation were below
10%, in the range of 100 to 500 ng/ml. Serum levels of
insulin-like growth factor binding protein-3 (IGFBP-3)
were determined by a commercially available ELISA (DSL,
Sinsheim, Germany). The sensitivity of that assay was
found to be lower than 0.8 ng/ml. Intraassay and interassay
coefficients of variation were below 10%, in the range of 4 to
40 ng/ml. Serum concentrations of tumor necrosis factor
(TNF)- were measured by a specific high sensitive
enzyme-linked immunoadsorbent assay kit (Quantakine,
R&D Systems, Minneapolis, Minnesota) with a sensitivity
0.18 pg/ml. All samples were run in duplicates, and the
average value of the two measurements is reported.
Measurement of local skeletal muscle IGF-I expression.
SKELETAL MUSCLE BIOPSIES. Percutaneous needle biop-
sies were obtained from the right vastus lateralis muscle
at least two days before exercise testing, as described
previously (9).
MEASUREMENT OF IGF-I MESSENGER RIBONUCLEIC ACID
(mRNA). To quantify IGF-I and IGF-I receptor mRNA,
real-time PCR using the Light Cycler System (Roche
Diagnostics Inc., Mannheim, Germany) was used. Briefly,
aliquots (1 g) of isolated total RNA was reverse tran-
scribed in a volume of 25 l into cDNA using random
hexamers; 1 l of cDNA was added to the PCR reaction
containing the following specific primers: IGF-I-U: 5-
CACCATGTCCTCCTCGCATCT-3, IGF-I-L: 5-
ATCCACGATGCCTGTCTGAGG-3, IGF-I recep-
tor-U: 5-GGAAGCGGAGAGATGTCATG-3 and
IGF-I receptor-L: 5-ATGGATGCGGTACAAT-
GTGA-3. The results for IGF-I and IGF-I receptor
expression are expressed as ratio over 18SrRNA, which was
amplified as house keeping gene using the following primers
18S rRNA-U: 5-TAGAGGGACAAGTGGCGTTC-3
and 18S rRNA-L: 5-TGTACAAAGGGCAGGGACTT-
3. The variability for triplicate measurements was 5%.
QUANTIFICATION OF IGF-I PROTEIN. Expression of IGF-I
protein was analyzed by Western blot using a monoclonal
anti-IGF-I antibody (clone Sm1.2, Upstate Biotechnology,
Lake Placid, New York) followed by densitometry. Briefly,
30 g of skeletal muscle proteins were separated on a 15%
SDS-polyacrylamide-gel, followed by electrotransfer to a
polyvinylidene fluoride membrane (Roth GmbH,
Karlsruhe, Germany). The transferred proteins were incu-
bated with a 1:500 dilution of the anti-IGF-I antibody at
4°C overnight. The bound antibody was detected by a
peroxidase coupled antimouse antibody followed by a
chemiluminescent reaction using luminol (SuperSignal
West Pico, Pierce Rockford, Illinois). To quantify IGF-I
protein the blots were analyzed by densitometry with a 1-D
analysis software package (One-Dscan, Scanalytics, Bil-
lerica, Massachusetts). To compensate for blot to blot
variations, an internal standard was loaded on each SDS-
polyacrylamide-gel, and the densitometry results were ex-
pressed as ratio between sample and standard intensity.
Abbreviations and Acronyms
CHF  chronic heart failure
CMP  cardiomyopathy
DCM  dilated cardiomyopathy
GH  growth hormone
HS  healthy subjects
IGF-I  insulin-like growth factor-I
IGFBP-3  insulin-like growth factor binding protein-3
IHD  ischemic heart disease
LVEF  left ventricular ejection fraction
mRNA  messenger ribonucleic acid
TNF-  tumor necrosis factor-
VO2max  maximal oxygen uptake
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Determination of lower limb muscle cross-sectional area.
In a subgroup of 10 CHF patients and 8 healthy controls
the muscle cross-sectional area was measured by computed
tomography at the mid-femur level as an established mor-
phologic parameter for skeletal muscle mass (6). Using a
Somatom Plus 4 CT-scanner (Siemens, Erlangen, Ger-
many) sections were made halfway between the major
trochanter and the medial condylus of the femur (slice
thickness 5 mm, 130 mA). Cross-sectional areas of all upper
right limb muscles and the quadriceps muscle were sepa-
rately determined by manual tracing, using the built-in CT
software VB 40 C.
Determination of quadriceps muscle function. Maximal
isometric tension development and muscle fatigability were
measured in the quadriceps muscles of the same patient
subgroup in whom muscle cross-sectional area was deter-
mined. Using a calibrated isometric force transducer (Mech-
anotronik, Hagen, Germany) with a minimal resolution of
1 N, the peak force at maximal voluntary quadriceps
contraction for 20 s was quantified five times with 1 min
resting intervals. Peak force and decrease of force over the
20-s period were averaged for the five tests.
Statistical analysis. Data were tested for normal distribu-
tion using the Kolmogorov-Smirnov test and for homoge-
neity of variances by Levene’s test. Mean value  standard
error was calculated for all variables. Because all data were
normally distributed, intergroup comparisons were made
using the two-sided Student’s t test. Linear regression
analysis was performed to assess the relationship between
local IGF-I expression and quadriceps muscle function/
cross-sectional area. A p value 0.05 was considered
statistically significant.
RESULTS
Baseline characteristics. A total of 47 CHF patients
(58.0  1.4 years, LVEF 23  1%) and 15 healthy
age-matched subjects (58.5  3.2 years, LVEF 70  2%)
were enrolled in the study (Table 1). The majority of CHF
patients were diagnosed with postischemic CHF (n 27 vs.
n  20 with DCM). Left ventricular ejection fraction was
not significantly different between dilated or ischemic CMP
(25 2% vs. 22 2%, p NS). Forty-three CHF patients
(91.5%) received angiotensin-converting enzyme inhibitors,
40 (85.1%) were on digitalis, 41 (87.2%) on diuretic
medications and 19 (40.4%) on beta receptor blockers. As
determined by the criterion of unintentional documented
weight loss of at least 7.5% of previous normal weight over
the last six months, all patients were noncachectic (5).
Maximal oxygen uptake (VO2 max), as determined by
bicycle ergospirometry, was significantly reduced in patients
with CHF (14.4  0.5 vs. 26.2  1.4 ml/kg·min in HS,
p  0.001).
Systemic levels of GH, IGF-I and IGFBP-3. The 47
CHF patients tended to have higher systemic GH levels
(1.14 0.23 ng/ml vs. 0.48 0.25 ng/ml in HS); however,
due to the considerable variation of individual values within
the groups, this difference was not statistically significant
(p  0.134) (Table 2). Although GH binding protein levels
were reduced in CHF patients (685 65 pmol/l in CHF vs.
917  110 pmol/l, p  0.08), this difference was not
significant either. No alterations in both IGF-I and
IGFBP-3 were observed between CHF patients and HS. In
a subgroup analysis, CHF patients with a body mass index
of 25 kg/m2 showed signs of peripheral GH resistance, as
indicated by elevated GH and reduced IGF-I levels. The
IGF-I/GH ratio was reduced in patients with a body mass
index 25 kg/m2 (Table 2).
Local expression of IGF-I/IGF-I receptor. The expres-
sion of IGF-I in skeletal muscle biopsies was assessed by
two independent methods: Western blot analysis and real-
time PCR (Light Cycler). Insulin-like growth factor-I
mRNA expression was significantly lower in patients with
CHF (6.7  0.4 in CHF vs. 14.0  0.9 arbitrary units in
HS, p  0.001). Specific Western blot analysis confirmed
these results on the IGF-I protein level (0.66  0.06 in
CHF vs. 1.29 0.15 arbitrary units in HS, p 0.001) (Fig.
1). The reduction in local IGF-I expression was accompa-
nied by an increase in local IGF-I receptor mRNA (86.8 
5.4 in CHF vs. 23.1 1.8 arbitrary units in HS, p 0.001)
(Fig. 2). As a consequence, the ratio IGF-I/IGF-I receptor
Table 1. Baseline Characteristics of Patients with Chronic Heart
Failure and Healthy Subjects
CHF
(n  47)
Healthy Subjects
(n  15)
Age, yrs 58.0  1.4 58.5  3.2
VO2max, ml·kg
1·min1 14.4  0.5 26.2  1.4
LVEF, % 23  1 70  2
No. DCM/IHD, (n) 20/27 —
NYHA 0/5/30/12 —
(No. in class I/II/III/IV)
CHF  chronic heart failure; CMP  cardiomyopathy; DCM  dilated cardiomy-
opathy; VO2 max  maximal oxygen uptake.
Table 2. Serum Hormone Measurements
CHF
(n  47)
Healthy Subjects
(n  15) p
GH (ng/ml) 1.14  0.23 0.48  0.25 0.134
IGF-I (ng/ml) 175  10 170  12 0.802
IGFBP-3 (g/ml) 3.64  0.18 3.98  0.31 0.345
TNF- (pg/ml) 3.38  0.22 1.82  0.29 0.001
IGF-I/GH 2052  571 2393  657 0.067
Subgroup
Data
BMI < 25 kg/m2
(n  15)
BMI > 25 kg/m2
(n  32) p
Age (yrs) 60.5  2.5 56.8  1.6 0.115
BMI (kg/m2) 22.5  0.5 29.0  0.4  0.001
VO2max (ml/kg min) 13.8  0.7 14.7  0.7 0.470
GH (ng/ml) 1.96  0.54 0.76  0.20 0.005
IGF-I (ng/ml) 145  17 189  12 0.038
IGFBP-3 (g/ml) 3.3  0.4 3.8  0.2 0.108
TNF- (pg/ml) 3.45  0.37 3.35  0.28 0.832
IGF-I/GH 637  460 2714  789 0.003
BMI  body mass index; GH  growth hormone; IGF-I  insulin-like growth
factors I; IGFBP-3  IGF binding protein-3; TNF-  tumor necrosis factor-.
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was significantly reduced in CHF (0.094  0.010 in CHF
vs. 0.664  0.064 in HS, p  0.001).
Skeletal muscle cross-sectional area and maximal isomet-
ric force. Patients and HS of this subgroup did not differ
significantly from the total study group in any relevant
baseline parameter. Both total and quadriceps muscle cross-
sectional areas were reduced in CHF patients, as compared
with HS (Table 3). There was a trend toward a reduced
maximal isometric contraction of the quadriceps muscle in
CHF patients (p  0.1). Chronic heart failure patients had
a significantly greater muscle fatigability as assessed by
percent decrease of maximal force during the 20-s contrac-
tion (19  5% vs. 4  2%, p  0.014).
Correlation between local IGF-I expression and skeletal
muscle cross-sectional area. In the subgroup of CHF
patients and HS, with quantification of both quadriceps
muscle cross-sectional area and maximal isometric voluntary
contraction, a significant correlation between IGF-I mRNA
and cross-sectional area (R  0.75, p  0.01) and between
IGF-I protein and cross-sectional area (R 0.75, p 0.01)
was observed (Fig. 3).
DISCUSSION
Studies in patients with advanced heart failure and cardiac
cachexia have revealed a possible involvement of GH and
IGF-I in muscle catabolism. It has been shown that skeletal
muscle dysfunction and loss of lean muscle bulk can occur in
noncachectic patients with CHF (2,5,6). To determine
whether alterations in systemic or local IGF-I levels may
contribute to skeletal muscle dysfunction and exercise intol-
erance even before the development of cachexia, we initiated
this first study investigating local IGF-I expression in
skeletal muscle biopsies of noncachectic CHF patients. Two
key messages emerge from this study:
1. Expression of IGF-I is considerably reduced (by more
than 50%) in the skeletal muscle of noncachectic patients
with severe CHF as compared with HS, although serum
Figure 1. Representative Western blots for insulin-like growth factor (IGF)-I protein are presented in A. (B) Local expression of IGF-I messenger
ribonucleic acid (mRNA). ***p  0.001 vs. healthy subjects. CHF  chronic heart failure.
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concentrations of IGF-I, GH and their binding proteins
remained unchanged. In a subgroup (body mass index
25 kg/m2), IGF-I decreased, whereas GH increased
significantly, consistent with the development of a pe-
ripheral GH-resistance.
2. Local IGF-I expression was closely correlated with
muscle cross-sectional area, indicating that local IGF-I
deficiency might contribute to loss of muscle bulk in
CHF.
Role of systemic versus local levels of IGF-I. Although
the clinical picture of cardiac cachexia is well known in
patients with advanced heart failure, the factors that deter-
mine who is at risk for this progressive catabolic syndrome
remain unclear. Different endocrine systems have been
accused of being involved in this process:
1. An imbalance between catabolic and anabolic steroids
with an elevated cortisol/dihydroepiandrosterone ratio
has been observed in CHF patients (3,5).
2. An increased resting metabolic rate due to high levels of
circulating catecholamines has been reported in CHF
(4).
3. Various cytokines are activated in CHF (i.e., TNF-,
IL-6 and others) and have been shown to contribute to
loss of muscle bulk and cachexia (3).
4. As a key regulator of normal growth, hypertrophy and
atrophy of tissues, the GH/IGF-I axis has recently
received more attention as a potential factor for muscle
catabolism and wasting in CHF. Elevated levels of GH
with inappropriately normal serum levels of IGF-I have
been described in cardiac cachexia (5).
All studies mentioned above shared the same methodolog-
ical approach, i.e., assessment of serum hormone levels. The
underlying hypothesis to justify this approach is that endog-
enous or exogenous stimuli (i.e. endotoxins) induce changes
in endocrine secretion and that, therefore, serum hormone
levels reflect the activation state of the endocrine system
under investigation. This presumption may be correct for
hormones like cortisol or GH. However, a significant
proportion of IGF-I is produced locally by skeletal muscle
fibers and acts as a paracrine, rather than endocrine,
regulator of skeletal muscle hypertrophy/atrophy (10). We
therefore measured local skeletal muscle IGF-I expression
to analyze its possible contribution to the pro-/anticatabolic
signaling in CHF.
Local IGF-I expression in severe CHF. As documented
in the present study, a reduction of skeletal muscle cross-
sectional area may occur before any changes in systemic
IGF-I levels can be detected. Local IGF-I expression was
substantially downregulated in the skeletal muscle of non-
cachectic patients with CHF despite normal IGF-I serum
concentrations. Insulin-like growth factor-I receptor ex-
pression, on the other hand, increased, indicating a possible
feedback mechanism between local IGF-I concentrations
and receptor density.
Local skeletal muscle IGF-I expression responds to
stimuli from two different sources: Serum GH has the
potential to augment local IGF-I expression. This mecha-
nism is important for normal growth and development of
the organism. It has been previously shown that a state of
GH resistance may develop in patients with advanced CHF
(6). Skeletal muscle IGF-I expression is modulated in
response to alterations in muscle use. In animal experiments
it has been shown that muscle unloading resulted in growth
retardation and decreased skeletal muscle IGF-I expression
in neonatal rats (11).
The IGF-I receptor has a central role in normal cellular
proliferation, as well as in transformation processes. Acti-
vation of the receptor after binding of IGF-I elicits a
repertoire of cellular responses including proliferation and
protection of cells from programmed cell death. Overex-
pression of the IGF-I receptor results in the malignant
transformation of cultured cells; conversely, downregulation
of IGF-I receptor levels can reverse the transformed phe-
notype of tumor cells and may render them sensitive to
apoptosis in vivo (12,13).
Increased prevalence of apoptosis has also been observed
Figure 2. Local expression of insulin-like growth factor (IGF)-I receptor
messenger ribonucleic acid (mRNA). CHF  chronic heart failure. ***p 
0.001 vs. healthy subjects.
Table 3. Skeletal Muscle Mass and Function
CHF
(n  10)
Healthy Subjects
(n  8) p
Total muscle area (cm2) 133  7 172  6 0.001
Quadriceps muscle area (cm2) 59  4 82  4 0.001
Peak isometric force (N) 237  31 283  31 0.100
Force decline 20 s (N/s) 2.3  0.52 0.6  0.33 0.022
Force after 20 s (% of peak) 81.2  4.5 96.1  2.3 0.014
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in skeletal muscle biopsies from patients with CHF (14, 15).
It is, therefore, conceivable that the apoptotic process in the
skeletal muscle might be accelerated in response to a decline
in local IGF-I expression.
The significant up-regulation of IGF-I receptor expres-
sion we observed in skeletal muscle biopsies of CHF
patients could be interpreted as a “survival signal.” One
might speculate that skeletal myocytes respond to a pro-
apoptotic environment with increased levels of oxidative
stress and inflammatory cytokines, as present in CHF, by
augmenting their sensitivity to the anti-apoptotic factor
IGF-I. Alternatively, the local IGF-I deficiency, itself,
might act as a stimulus for increased IGF-I receptor
expression in skeletal myocytes.
The anti-apoptotic effects of IGF-I in the presence of
proinflammatory cytokines are supported by previous obser-
vations that IGF-I receptor activation prevents TNF--
induced cell death (16). However, it seems that in our study
population the increased expression of the IGF-I receptor
was not sufficient to compensate the local IGF-I deficit,
with the result that skeletal muscle atrophy (as measured by
the decrease of muscle cross-sectional area in CHF patients)
was not prevented.
Study limitations. Some limitations apply to our findings.
Only male patients 70 years of age were included in the
present study. It may well be that females or older patients
show different patterns of local/systemic IGF-I alterations
in CHF. Another aspect requiring further investigation
concerns differences in muscle atrophy between the upper
and lower extremities. Anker et al. (2) have shown that in
noncachectic patients only leg muscle tissue is reduced. This
could be caused by different degrees of muscle disuse or
different sensitivities to catabolic stimuli.
Additional animal experiments and intervention studies
are necessary to confirm a causal role of IGF-I in skeletal
muscle apoptosis and atrophy in CHF for two reasons.
First, the differentiation between disuse-induced skeletal
muscle changes and intrinsic alterations caused by CHF
remains difficult in any clinical trial because it is impossible
to subject healthy control subjects to exactly the same level
of daily physical activity as observed in CHF patients.
Second, the local skeletal muscle IGF-I expression needs to
be correlated with the local apoptotic rate in the same
biopsy. However, the needle biopsy does not provide
enough material to reliably perform multiple methods in the
same patient—a limitation also experienced by other groups
(17). Further studies in animal models where sample size is
not an issue will close this gap.
Role of local IGF-I expression for skeletal muscle mass
and dysfunction. In the present study, skeletal muscle
fatigability was significantly increased, as documented by
the rapid decrease of contractile force over time. This
finding cannot be explained by skeletal muscle atrophy alone
because muscular properties seem to be differentially af-
fected. Although maximal strength depends on the number
of contractile filaments, fatigability is influenced by intra-
Figure 3. Correlation between right lower limb cross-sectional area (CSA) and insulin-like growth factor (IGF)-I messenger ribonucleic acid (mRNA) in
skeletal muscle biopsies obtained from the same thigh. A: y  0.16 x 3.8 (R  0.75, p  0.01).
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cellular energy stores and rapid resynthesis of phospho-
creatine. We and others have previously shown that oxida-
tive phosphorylation is attenuated in CHF patients; energy
transfer by means of mitochondrial creatine kinase is im-
paired, and overall ATP levels are reduced (18–20). These
factors could explain why muscle fatigability develops earlier
than does reduction of maximal contractile force.
Previous studies suggested that reduced serum IGF-I
levels are associated with reduced quadriceps cross-sectional
area and muscle strength (6). In the present study, however,
serum IGF-I levels in CHF patients were not significantly
different from those in HS, indicating that these patients
might be in a less advanced stage of CHF. However, in
these noncachectic patients, local muscular IGF-I expres-
sion and quadriceps cross-sectional area were significantly
reduced, suggesting that a local IGF-I deficit might be a
more important factor for muscle atrophy than a change in
IGF-I serum levels. This hypothesis is supported by the
correlation between local IGF-I expression and muscle
cross-sectional area.
Clinical implications. This study provides first-time evi-
dence that local IGF-I expression is substantially reduced in
skeletal muscle biopsies of noncachectic CHF patients and
may be a contributing factor to early loss of leg muscle mass
and muscular dysfunction in CHF.
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